Trevi Therapeutics (NASDAQ:TRVI) Given Buy Rating at D. Boral Capital

Trevi Therapeutics (NASDAQ:TRVI)‘s stock had its “buy” rating restated by stock analysts at D. Boral Capital in a report released on Thursday,Benzinga reports. They currently have a $19.00 price target on the stock. D. Boral Capital’s target price suggests a potential upside of 62.25% from the stock’s current price.

Several other research analysts also recently weighed in on TRVI. Oppenheimer boosted their target price on Trevi Therapeutics from $23.00 to $24.00 and gave the stock an “outperform” rating in a research note on Friday, November 14th. Stifel Nicolaus increased their price objective on shares of Trevi Therapeutics from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, December 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Trevi Therapeutics in a research report on Wednesday, October 8th. Morgan Stanley raised their price target on shares of Trevi Therapeutics from $18.00 to $19.00 and gave the stock an “overweight” rating in a report on Friday, November 14th. Finally, Leerink Partners boosted their price objective on shares of Trevi Therapeutics from $13.00 to $16.00 and gave the company an “outperform” rating in a report on Wednesday, November 19th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Trevi Therapeutics presently has an average rating of “Buy” and a consensus target price of $21.10.

Trevi Therapeutics Stock Performance

NASDAQ:TRVI opened at $11.71 on Thursday. The company’s 50-day simple moving average is $12.19 and its 200-day simple moving average is $9.45. Trevi Therapeutics has a fifty-two week low of $3.47 and a fifty-two week high of $14.39. The stock has a market capitalization of $1.50 billion, a P/E ratio of -31.65 and a beta of 0.91.

Trevi Therapeutics (NASDAQ:TRVI) last posted its earnings results on Thursday, November 13th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.02. On average, research analysts forecast that Trevi Therapeutics will post -0.49 EPS for the current year.

Institutional Investors Weigh In On Trevi Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TRVI. AQR Capital Management LLC raised its stake in shares of Trevi Therapeutics by 20.4% during the 1st quarter. AQR Capital Management LLC now owns 27,720 shares of the company’s stock valued at $174,000 after buying an additional 4,688 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Trevi Therapeutics by 31.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,143 shares of the company’s stock worth $278,000 after acquiring an additional 10,445 shares during the period. Millennium Management LLC grew its holdings in Trevi Therapeutics by 356.3% during the first quarter. Millennium Management LLC now owns 823,249 shares of the company’s stock worth $5,178,000 after acquiring an additional 642,830 shares during the period. Fred Alger Management LLC purchased a new position in Trevi Therapeutics during the first quarter valued at approximately $482,000. Finally, Strs Ohio acquired a new position in Trevi Therapeutics in the first quarter valued at approximately $52,000. 95.76% of the stock is owned by institutional investors and hedge funds.

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.